Oral epigallocatechin-3-gallate for treatment of dystrophic epidermolysis bullosa: a multicentre, randomized, crossover, double-blind, placebo-controlled clinical trial.

Abstract:

UNLABELLED:Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genodermatosis with severe blistering. No curative treatment is available. Scientific data indicated that epigallocatechin-3-gallate (EGCG), a green tea extract, might improve the phenotype of RDEB patients. In a multicentre, randomized, crossover, double-blind, placebo-controlled clinical trial, we evaluated a 4-month oral EGCG treatment regimen in 17 RDEB patients. We found that EGCG treatment was not more effective than placebo in modified intention to treat and per protocol analysis (n = 16; p = 0.78 and n = 10; p = 1 respectively). Tolerance was good. Specific organizational and technical difficulties of controlled randomized double-blind trials in EB patients are discussed. TRIAL REGISTRATION:US National Institutes of Health Clinical Trial Register ( NCT00951964 ).

journal_name

Orphanet J Rare Dis

authors

Chiaverini C,Roger C,Fontas E,Bourrat E,Bourdon-Lanoy E,Labrèze C,Mazereeuw J,Vabres P,Bodemer C,Lacour JP

doi

10.1186/s13023-016-0411-5

subject

Has Abstract

pub_date

2016-03-25 00:00:00

pages

31

issn

1750-1172

pii

10.1186/s13023-016-0411-5

journal_volume

11

pub_type

信件,随机对照试验
  • Genome sequencing and implications for rare disorders.

    abstract::The practice of genomic medicine stands to revolutionize our approach to medical care, and to realize this goal will require discovery of the relationship between rare variation at each of the ~ 20,000 protein-coding genes and their consequent impact on individual health and expression of Mendelian disease. The step-w...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章,评审

    doi:10.1186/s13023-019-1127-0

    authors: Posey JE

    更新日期:2019-06-24 00:00:00

  • Severe hepatopathy and neurological deterioration after start of valproate treatment in a 6-year-old child with mitochondrial tryptophanyl-tRNA synthetase deficiency.

    abstract:BACKGROUND:The first subjects with deficiency of mitochondrial tryptophanyl-tRNA synthetase (WARS2) were reported in 2017. Their clinical characteristics can be subdivided into three phenotypes (neonatal phenotype, severe infantile onset phenotype, Parkinson-like phenotype). RESULTS:Here, we report on a subject who pr...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章

    doi:10.1186/s13023-018-0822-6

    authors: Vantroys E,Smet J,Vanlander AV,Vergult S,De Bruyne R,Roels F,Stepman H,Roeyers H,Menten B,Van Coster R

    更新日期:2018-05-21 00:00:00

  • Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann-Pick disease type C: an observational cohort study.

    abstract:BACKGROUND:Niemann-Pick disease type C (NP-C) is a rare neurovisceral disease characterised by progressive neurological degeneration, where the rate of neurological disease progression varies depending on age at neurological onset. We report longitudinal data on functional disease progression and safety observations in...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章

    doi:10.1186/s13023-015-0284-z

    authors: Patterson MC,Mengel E,Vanier MT,Schwierin B,Muller A,Cornelisse P,Pineda M,NPC Registry investigators.

    更新日期:2015-05-28 00:00:00

  • Clinical features, treatment, and survival outcome of primary pulmonary NUT midline carcinoma.

    abstract:OBJECTIVE:NUT midline carcinoma (NMC), a rare type of squamous cell carcinoma, is genetically characterised by NUT midline carcinoma family member 1 (NUTM1) gene rearrangement. NMC can arise from the lungs; however, there is no standard for the management of primary pulmonary NMC. This study aimed to confirm the clinic...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章

    doi:10.1186/s13023-020-01449-x

    authors: Xie XH,Wang LQ,Qin YY,Lin XQ,Xie ZH,Liu M,Zhang JX,Ouyang M,Liu J,Gu YY,Li SY,Zhou CZ

    更新日期:2020-07-10 00:00:00

  • A quality improvement program to reduce the time on the lung transplant waiting list at the Nantes University Hospital.

    abstract:BACKGROUND:In 2010, the time on the lung transplant waiting list in Nantes University Hospital (NUH) was 9.2 months, compared to a French national median of about 4 months. The NUH transplant unit performs both heart and lung transplantations, which can be seen as competing activities. To fix the problem, the adult Cys...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章

    doi:10.1186/s13023-017-0748-4

    authors: Danner-Boucher I,Loppinet V,Boxus A,Dary C,Lambert AB,Prieur M,Vallet C,Tissot A

    更新日期:2018-02-08 00:00:00

  • Anophthalmia and microphthalmia.

    abstract::Anophthalmia and microphthalmia describe, respectively, the absence of an eye and the presence of a small eye within the orbit. The combined birth prevalence of these conditions is up to 30 per 100,000 population, with microphthalmia reported in up to 11% of blind children. High-resolution cranial imaging, post-mortem...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章,评审

    doi:10.1186/1750-1172-2-47

    authors: Verma AS,Fitzpatrick DR

    更新日期:2007-11-26 00:00:00

  • Future treatments for hereditary hemorrhagic telangiectasia.

    abstract::Hereditary Hemorrhagic Telangiectasia (HHT), also known as Rendu-Osler syndrome, is a genetic vascular disorder affecting 1 in 5000-8000 individuals worldwide. This rare disease is characterized by various vascular defects including epistaxis, blood vessel dilations (telangiectasia) and arteriovenous malformations (AV...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章,评审

    doi:10.1186/s13023-019-1281-4

    authors: Robert F,Desroches-Castan A,Bailly S,Dupuis-Girod S,Feige JJ

    更新日期:2020-01-07 00:00:00

  • Reimbursement of orphan drugs in Belgium: what (else) matters?

    abstract:BACKGROUND:Most orphan drugs do not meet traditional standards of cost-effectiveness. Yet, most orphan drugs are reimbursed, which implies that other factors are taken into account at the time of reimbursement. To increase accountability of decision-makers, there is a need for more transparency in the factors that play...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章

    doi:10.1186/s13023-014-0139-z

    authors: Picavet E,Cassiman D,Simoens S

    更新日期:2014-09-12 00:00:00

  • Validity and interexaminer reliability of a new method to quantify skin neurofibromas of neurofibromatosis 1 using paper frames.

    abstract:BACKGROUND:Skin neurofibromas represent one of the main clinical manifestations of neurofibromatosis 1, and their number varies greatly between individuals. Quantifying their number is an important step in the methodology of many clinical studies, but counting neurofibromas one by one in individuals with thousands of t...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章

    doi:10.1186/s13023-014-0202-9

    authors: Cunha KS,Rozza-de-Menezes RE,Andrade RM,Theos A,Luiz RR,Korf B,Geller M

    更新日期:2014-12-05 00:00:00

  • Outcomes of 4 years of molecular genetic diagnosis on a panel of genes involved in premature aging syndromes, including laminopathies and related disorders.

    abstract:BACKGROUND:Segmental progeroid syndromes are a heterogeneous group of rare and often severe genetic disorders that have been studied since the twentieth century. These progeroid syndromes are defined as segmental because only some of the features observed during natural aging are accelerated. METHODS:Since 2015, the M...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章

    doi:10.1186/s13023-019-1189-z

    authors: Grelet M,Blanck V,Sigaudy S,Philip N,Giuliano F,Khachnaoui K,Morel G,Grotto S,Sophie J,Poirsier C,Lespinasse J,Alric L,Calvas P,Chalhoub G,Layet V,Molin A,Colson C,Marsili L,Edery P,Lévy N,De Sandre-Giovannoli A

    更新日期:2019-12-11 00:00:00

  • Prevalence of Fabry disease in dialysis patients: Western Australia Fabry disease screening study - the FoRWARD study.

    abstract:AIM:To determine the prevalence of undiagnosed Fabry Disease (FD) in Western Australian (WA) patients undergoing dialysis. BACKGROUND:FD is a multisystem X-linked lysosomal storage disease caused by deficient activity of alpha-galactosidase-A (α-GAL-A). Affected individuals are at risk of developing small-fibre neurop...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章

    doi:10.1186/s13023-019-1290-3

    authors: Jahan S,Sarathchandran S,Akhter S,Goldblatt J,Stark S,Crawford D,Mallett A,Thomas M

    更新日期:2020-01-13 00:00:00

  • Glycogenosome accumulation in the arrector pili muscle in Pompe disease.

    abstract:BACKGROUND:Glycogenosis type II or Pompe disease is an autosomal-recessive lysosomal storage disease due to mutations in the gene encoding acid alpha-glucosidase (GAA), an enzyme required for lysosomal glycogen degradation. The disease predominantly affects the skeletal and respiratory muscles but there is growing evid...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章

    doi:10.1186/1750-1172-9-17

    authors: Katona I,Weis J,Hanisch F

    更新日期:2014-02-05 00:00:00

  • Hermansky-Pudlak syndrome and oculocutaneous albinism in Chinese children with pigmentation defects and easy bruising.

    abstract:BACKGROUND:Determining the etiology of oculocutaneous albinism is important for proper clinical management and to determine prognosis. The purpose of this study was to genotype and phenotype eight adopted Chinese children who presented with oculocutaneous albinism and easy bruisability. RESULTS:The patients were evalu...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章

    doi:10.1186/s13023-019-1023-7

    authors: Power B,Ferreira CR,Chen D,Zein WM,O'Brien KJ,Introne WJ,Stephen J,Gahl WA,Huizing M,Malicdan MCV,Adams DR,Gochuico BR

    更新日期:2019-02-21 00:00:00

  • Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012.

    abstract:BACKGROUND:Orphan designated medicinal products benefit from regulatory and economic incentives for orphan drug development. Approximately 40% of orphan designations target rare neoplastic disorders, referring to rare cancers. In order to provide more insights in drugs for rare neoplastic disorders that are under devel...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章

    doi:10.1186/s13023-017-0578-4

    authors: Pauwels K,Huys I,Casteels M,Larsson K,Voltz C,Penttila K,Morel T,Simoens S

    更新日期:2017-02-16 00:00:00

  • Determinants of impaired quality of life in patients with fibrous dysplasia.

    abstract:BACKGROUND:Fibrous dysplasia is a rare bone disorder, commonly associated with pain, deformity and fractures, which may significantly impact on quality of life. In this study we evaluate quality of life in patients with fibrous dysplasia using the Short Form-36 and the Brief Pain Inventory questionnaires. Data were com...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章

    doi:10.1186/s13023-017-0629-x

    authors: Majoor BCJ,Andela CD,Bruggemann J,van de Sande MAJ,Kaptein AA,Hamdy NAT,Dijkstra PDS,Appelman-Dijkstra NM

    更新日期:2017-04-27 00:00:00

  • Evaluation of the frequency of non-motor symptoms of Parkinson's disease in adult patients with Gaucher disease type 1.

    abstract:BACKGROUND:Gaucher disease (GD) is caused by deficiency of beta-glucocerebrosidase (GCase) due to biallelic variations in the GBA1 gene. Parkinson's disease (PD) is the second most common neurodegenerative condition. The classic motor symptoms of PD may be preceded by many non-motor symptoms (NMS), which include hyposm...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章

    doi:10.1186/s13023-019-1079-4

    authors: Wilke MVMB,Dornelles AD,Schuh AS,Vairo FP,Basgalupp SP,Siebert M,Nalin T,Piltcher OB,Schwartz IVD

    更新日期:2019-05-10 00:00:00

  • Rare diseases and orphan drugs: 500 years ago.

    abstract::In 1581 Rembert Dodoens wrote "Medicinalium observationum exempla rara, recognita et aucta" a Latin book about the diagnosis and treatment of disorders with a low prevalence. ...

    journal_title:Orphanet journal of rare diseases

    pub_type: 传,历史文章,信件

    doi:10.1186/s13023-015-0353-3

    authors: Dooms MM

    更新日期:2015-12-21 00:00:00

  • KH176 under development for rare mitochondrial disease: a first in man randomized controlled clinical trial in healthy male volunteers.

    abstract:BACKGROUND:Mitochondrial disorders are a clinically, biochemically and genetically heterogeneous group of multi-system diseases, with an unmet medical need for treatment. KH176 is an orally bio-available small molecule under development for the treatment of mitochondrial(-related) diseases. The compound is a member of ...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章,随机对照试验

    doi:10.1186/s13023-017-0715-0

    authors: Koene S,Spaans E,Van Bortel L,Van Lancker G,Delafontaine B,Badilini F,Beyrath J,Smeitink J

    更新日期:2017-10-16 00:00:00

  • Quality of life of children with achondroplasia and their parents - a German cross-sectional study.

    abstract:BACKGROUND:Achondroplasia is the most common form of disproportionate short stature and might affect not only the quality of life of the affected child but also that of the parents. OBJECTIVES:We aimed to investigate the quality of life of children with achondroplasia from child- and parent perspective as well as the ...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章

    doi:10.1186/s13023-019-1171-9

    authors: Witt S,Kolb B,Bloemeke J,Mohnike K,Bullinger M,Quitmann J

    更新日期:2019-08-09 00:00:00

  • Family burden in inherited ichthyosis: creation of a specific questionnaire.

    abstract:BACKGROUND:The concept of individual burden, associated with disease, has been introduced recently to determine the "disability" caused by the pathology in the broadest sense of the word (psychological, social, economic, physical). Inherited ichthyosis belong to a large heterogeneous group of Mendelian Disorders of Cor...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章

    doi:10.1186/1750-1172-8-28

    authors: Dufresne H,Hadj-Rabia S,Méni C,Sibaud V,Bodemer C,Taïeb C

    更新日期:2013-02-15 00:00:00

  • Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset Fabry mutation (IVS4 + 919G > A).

    abstract:BACKGROUND:In Taiwan, DNA-based newborn screening showed a surprisingly high incidence of a cardiac Fabry mutation (IVS4 + 919G > A). The prevalence of this mutation is too high to be believed that it is a real pathogenic mutation. The purpose of this study is to identify the cardiac pathologic characteristics in patie...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章

    doi:10.1186/1750-1172-9-96

    authors: Hsu TR,Sung SH,Chang FP,Yang CF,Liu HC,Lin HY,Huang CK,Gao HJ,Huang YH,Liao HC,Lee PC,Yang AH,Chiang CC,Lin CY,Yu WC,Niu DM

    更新日期:2014-07-01 00:00:00

  • Two new Rett syndrome families and review of the literature: expanding the knowledge of MECP2 frameshift mutations.

    abstract:BACKGROUND:Rett syndrome (RTT) is an X-linked dominant neurodevelopmental disorder, which is usually caused by de novo mutations in the MECP2 gene. More than 70% of the disease causing MECP2 mutations are eight recurrent C to T transitions, which almost exclusively arise on the paternally derived X chromosome. About 10...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章,评审

    doi:10.1186/1750-1172-6-58

    authors: Ravn K,Roende G,Duno M,Fuglsang K,Eiklid KL,Tümer Z,Nielsen JB,Skjeldal OH

    更新日期:2011-08-30 00:00:00

  • China launched a pilot project to improve its rare disease healthcare levels.

    abstract::China is facing the great challenge of serving the world's largest rare disease population. It is necessary to develop a specific medical plan to increase the levels of optimal prevention, diagnosis and treatment of rare diseases under the existing clinical service structures in China. In 2013, China launched its firs...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章

    doi:10.1186/1750-1172-9-14

    authors: Cui Y,Zhou X,Han J

    更新日期:2014-01-27 00:00:00

  • Nerve ultrasound characterizes AMN polyneuropathy as inhomogeneous and focal hypertrophic.

    abstract:OBJECTIVE:High-resolution nerve ultrasound (HRUS) is a painless tool to quickly evaluate peripheral nerve morphology in vivo. This study set out to characterize peripheral nerve involvement in X-linked adrenomyeloneuropathy (AMN) by HRUS. METHODS:Thirteen adults with genetically proven AMN were examined using the Ultr...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章

    doi:10.1186/s13023-018-0939-7

    authors: Rattay TW,Just J,Röben B,Hengel H,Schüle R,Synofzik M,Söhn AS,Winter N,Dammeier N,Schöls L,Grimm A

    更新日期:2018-11-03 00:00:00

  • Evaluation of SHOX copy number variations in patients with Müllerian aplasia.

    abstract:BACKGROUND:Müllerian aplasia (MA) characterized by congenital loss of functional uterus and vagina is one of the most difficult disorders of female reproductive health. Despite of growing interest in this research field, the cause of the disorder for the majority of patients is still unknown. A recent report of partial...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章

    doi:10.1186/1750-1172-6-53

    authors: Sandbacka M,Halttunen M,Jokimaa V,Aittomäki K,Laivuori H

    更新日期:2011-08-02 00:00:00

  • Economic impact of screening for X-linked Adrenoleukodystrophy within a newborn blood spot screening programme.

    abstract:BACKGROUND:A decision tree model was built to estimate the economic impact of introducing screening for X-linked adrenoleukodystrophy (X-ALD) into an existing tandem mass spectrometry based newborn screening programme. The model was based upon the UK National Health Service (NHS) Newborn Blood Spot Screening Programme ...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章

    doi:10.1186/s13023-018-0921-4

    authors: Bessey A,Chilcott JB,Leaviss J,Sutton A

    更新日期:2018-10-11 00:00:00

  • Alpha-1 antitrypsin deficiency: outstanding questions and future directions.

    abstract:BACKGROUND:Alpha-1 antitrypsin deficiency (AATD) is a rare hereditary condition that leads to decreased circulating alpha-1 antitrypsin (AAT) levels, significantly increasing the risk of serious lung and/or liver disease in children and adults, in which some aspects remain unresolved. METHODS:In this review, we summar...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章,评审

    doi:10.1186/s13023-018-0856-9

    authors: Torres-Durán M,Lopez-Campos JL,Barrecheguren M,Miravitlles M,Martinez-Delgado B,Castillo S,Escribano A,Baloira A,Navarro-Garcia MM,Pellicer D,Bañuls L,Magallón M,Casas F,Dasí F

    更新日期:2018-07-11 00:00:00

  • Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management.

    abstract::Cerebrotendinous xanthomatosis (CTX) OMIM#213700 is a rare autosomal-recessive lipid storage disease caused by mutations in the CYP27A1 gene; this gene codes for the mitochondrial enzyme sterol 27-hydroxylase, which is involved in bile acid synthesis. The CYP27A1 gene is located on chromosome 2q33-qter and contains ni...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章,评审

    doi:10.1186/s13023-014-0179-4

    authors: Nie S,Chen G,Cao X,Zhang Y

    更新日期:2014-11-26 00:00:00

  • The clinical relevance of outcomes used in late-onset Pompe disease: can we do better?

    abstract::Pompe disease/glycogen storage disease type II, is a rare, lysosomal storage disorder associated with progressive proximal myopathy, causing a gradual loss of muscular function and respiratory insufficiency. Studies of patients with late-onset Pompe disease have used endpoints such as the 6-minute walking test (6MWT) ...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章,评审

    doi:10.1186/1750-1172-8-160

    authors: Lachmann R,Schoser B

    更新日期:2013-10-12 00:00:00

  • A guide to writing systematic reviews of rare disease treatments to generate FAIR-compliant datasets: building a Treatabolome.

    abstract:BACKGROUND:Rare diseases are individually rare but globally affect around 6% of the population, and in over 70% of cases are genetically determined. Their rarity translates into a delayed diagnosis, with 25% of patients waiting 5 to 30 years for one. It is essential to raise awareness of patients and clinicians of exis...

    journal_title:Orphanet journal of rare diseases

    pub_type: 杂志文章

    doi:10.1186/s13023-020-01493-7

    authors: Atalaia A,Thompson R,Corvo A,Carmody L,Piscia D,Matalonga L,Macaya A,Lochmuller A,Fontaine B,Zurek B,Hernandez-Ferrer C,Rheinard C,Gómez-Andrés D,Desaphy JF,Schon K,Lohmann K,Jennings MJ,Synofzik M,Riess O,Yaou RB,

    更新日期:2020-08-12 00:00:00